Amneal Pharma Gets FDA Nod for Infection Fighting Drug Combination
Provided by
Dow Jones
By Dean Seal
Amneal Pharmaceuticals said the Food and Drug Administration has approved its abbreviated new drug application for ciprofloxacin and dexamethasone otic suspension, a combination used to treat infections.
The Bridgewater, N.J.-based company said the combination of ciprofloxacin and dexamethasone is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in acute otitis externa due to staphylococcus aureus and pseudomonas aeruginosa.
The most common adverse reactions reported with the combination were ear pain, ear discomfort and ear pruritus.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
March 25, 2024 16:39 ET (20:39 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
How Anti-Obesity Drugs Are Innovating the Healthcare Market
-
Why Immigration Has Boosted Job Gains and the Economy
-
What to Invest in During High Inflation
-
Never Mind Market Efficiency: Are the Markets Sensible?
-
Starbucks Stock Could Use a Pick-Me-Up After Big Selloff; Is it a Buy?
-
5 Cheap Stocks to Buy From an Attractive Part of the Market
-
Markets Brief: All Eyes On Inflation
-
5 Things We Learned From the Q1 Earnings Season
-
Baidu Earnings: Advertising Weakness Offset by Continued Growth In Cloud Business
-
Going Into Earnings, Is Target Stock a Buy, a Sell, or Fairly Valued?
-
Walmart Earnings: Low Prices and Strong Digital Presence Drive Market Share Gains
-
After Earnings and a Big Selloff, Is Shopify Stock a Buy, a Sell, or Fairly Valued?
-
Cisco Earnings: Positive Guidance and Splunk Inclusion Align With Our Long-Term Thesis
-
3 Warren Buffett Stocks to Buy After Berkshire Hathaway’s Just-Released 13F Filing
-
Going Into Earnings, Is Nvidia Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Arista Stock a Buy, a Sell, or Fairly Valued?